JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on November 10, 2004; DOI: 10.1124/jpet.104.077263


0022-3565/05/3123-1272-1279$20.00
JPET 312:1272-1279, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.077263v1
312/3/1272    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bourlier, V.
Right arrow Articles by Galitzky, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bourlier, V.
Right arrow Articles by Galitzky, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-PHENYLALANINE
*THIOPHENE
Medline Plus Health Information
*Stem Cells

CELLULAR AND MOLECULAR

Protease Inhibitor Treatments Reveal Specific Involvement of Matrix Metalloproteinase-9 in Human Adipocyte Differentiation

Virginie Bourlier, Alexia Zakaroff-Girard, Sandra De Barros, Christophe Pizzacalla, Véronique Durand de Saint Front, Max Lafontan, Anne Bouloumié, and Jean Galitzky

Unité de Recherche sur les Obésités, Institut National de la Santé et de la Recherche Médicale, Institut Louis Bugnard, Hôpital Rangueil, Université Paul Sabatier, Toulouse, France (V.B., A.Z.-G., S.D.B., C.P., V.D.d.S.F., M.L., J.G.); and Institut für Kardiovaskuläre Physiologie, Frankfurt/Main, Germany (A.B.)

We previously showed that human and murine 3T3-F442A preadipocytes produced and released matrix metalloproteinases (MMPs) 2 and 9 and that a treatment by MMP inhibitors resulted in the blockade of murine fat cell adipose conversion. In parallel, investigators reported that other protease inhibitors, the human immunodeficiency virus (HIV) protease inhibitors (PIs) involved in lipodystrophy in humans, also reduced the adipocyte differentiation process of several murine cell lines. The present work was performed to define the effects of MMP inhibitors and HIV-PIs on the human adipocyte differentiation process, to clarify the involvement of MMPs in the control of human adipogenesis, and to determine whether HIV-PIs interact with MMPs in the control of this process. The effect of two MMP inhibitor and four HIV-PI treatments on the differentiation of primary culture human preadipocytes, as well as the putative relationships between HIV-PIs and MMP-2 and -9 expression, release, or activity were investigated. We showed that MMP inhibitors and HIV-PIs reduced the human adipocyte differentiation process as assessed by the decrease of cell protein and/or triglyceride contents and expression of fatty acid binding protein and hormone-sensitive lipase, two adipocyte markers. Unlike MMP inhibitors, HIV-PIs were devoid of any effect per se on recombinant MMP-2 and 9 activities but reduced the expression and release of MMP-9 by human preadipocytes. Thus, the present study indicates that the modulation of the extracellular matrix components through the production and/or activity of MMPs, and, more precisely, MMP-9 might be a key factor in the regulation of human adipose tissue development.


Received for publication September 6, 2004
Accepted November 9, 2004.

Address correspondence to: Dr. Virginie Bourlier, Institut National de la Santé et de la Recherche Médicale U586, 37 Allées Jules Guesde, 31073 Toulouse, France. E-mail: virginie.bourlier{at}cict.fr




This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
L. C. Chao, S. J. Bensinger, C. J. Villanueva, K. Wroblewski, and P. Tontonoz
Inhibition of Adipocyte Differentiation by Nur77, Nurr1, and Nor1
Mol. Endocrinol., December 1, 2008; 22(12): 2596 - 2608.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
Y. Wu and C. M. Smas
Wdnm1-like, a new adipokine with a role in MMP-2 activation
Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E205 - E215.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
H. R. Lijnen
Angiogenesis and obesity
Cardiovasc Res, May 1, 2008; 78(2): 286 - 293.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
V. Bourlier, A. Zakaroff-Girard, A. Miranville, S. De Barros, M. Maumus, C. Sengenes, J. Galitzky, M. Lafontan, F. Karpe, K.N. Frayn, et al.
Remodeling Phenotype of Human Subcutaneous Adipose Tissue Macrophages
Circulation, February 12, 2008; 117(6): 806 - 815.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C. Muratori, A. Sistigu, E. Ruggiero, M. Falchi, I. Bacigalupo, C. Palladino, E. Toschi, and M. Federico
Macrophages Transmit Human Immunodeficiency Virus Type 1 Products to CD4-Negative Cells: Involvement of Matrix Metalloproteinase 9
J. Virol., September 1, 2007; 81(17): 9078 - 9087.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. De Barros, A. Zakaroff-Girard, M. Lafontan, J. Galitzky, and V. Bourlier
Inhibition of Human Preadipocyte Proteasomal Activity by HIV Protease Inhibitors or Specific Inhibitor Lactacystin Leads to a Defect in Adipogenesis, Which Involves Matrix Metalloproteinase-9
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 291 - 299.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.